{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:24:15Z","timestamp":1794000255940,"version":"4.8.0"},"reference-count":12,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jtocrr.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JTO Clinical and Research Reports"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtocrr.2026.101042","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:15:45Z","timestamp":1782803745000},"page":"101042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Envisioning Low-Dose Tarlatamab"],"prefix":"10.1016","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6371-4527","authenticated-orcid":false,"given":"Molly C.","family":"Tokaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"Pantelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Nock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Ratain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garth W.","family":"Strohbehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtocrr.2026.101042_bib1","series-title":"Multi-discipline review","year":"2024"},{"key":"10.1016\/j.jtocrr.2026.101042_bib2","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1056\/NEJMp2109826","article-title":"The drug-dosing conundrum in oncology - when less is more","volume":"385","author":"Shah","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101042_bib3","series-title":"Services USDoHaH","article-title":"Optimizing the dosage of human prescription drugs and biological products for the treatment of oncologic diseases: guidance for industry","year":"2024"},{"key":"10.1016\/j.jtocrr.2026.101042_bib4","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101042_bib5","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101042_bib6","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtocrr.2026.101042_bib7","doi-asserted-by":"crossref","first-page":"4688","DOI":"10.1158\/1078-0432.CCR-25-2134","article-title":"Tarlatamab exposure-efficacy and exposure-safety relationships to inform dose selection in patients with small cell lung cancer (SCLC)","volume":"31","author":"Chen","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtocrr.2026.101042_bib8","doi-asserted-by":"crossref","first-page":"2827","DOI":"10.1200\/JCO-25-00488","article-title":"Totality of the evidence: optimizing dosage selection strategies in oncology","volume":"43","author":"Levit","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtocrr.2026.101042_bib9","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3390\/ph17050591","article-title":"Change in neurocognitive function in patients who receive CAR-T cell therapies: a steep hill to climb","volume":"17","author":"Strongyli","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jtocrr.2026.101042_bib10","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10549-022-06755-5","article-title":"Patient-centered dosing: oncologists\u2019 perspectives about treatment-related side effects and individualized dosing for patients with metastatic breast cancer (MBC)","volume":"196","author":"Loeser","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jtocrr.2026.101042_bib11","doi-asserted-by":"crossref","first-page":"e1807","DOI":"10.1200\/OP.22.00427","article-title":"Oncologists\u2019 perspectives on individualizing dose selection for patients with metastatic cancer","volume":"18","author":"Jimenez","year":"2022","journal-title":"JCO Oncol Pract"},{"key":"10.1016\/j.jtocrr.2026.101042_bib12","article-title":"Pazdur at FDA-ASCO workshop: Failure to optimize the dose is akin to building a house on quicksand","volume":"48","author":"Tracey","year":"2022","journal-title":"Cancer Lett"}],"container-title":["JTO Clinical and Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326000937?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666364326000937?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T20:28:03Z","timestamp":1793996883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666364326000937"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":12,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666364326000937"],"URL":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101042","relation":{},"ISSN":["2666-3643"],"issn-type":[{"value":"2666-3643","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Envisioning Low-Dose Tarlatamab","name":"articletitle","label":"Article Title"},{"value":"JTO Clinical and Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtocrr.2026.101042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"101042"}}